Oruka Therapeutics (NASDAQ:ORKA) Director Carl Dambkowski Sells 22,417 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Director Carl Dambkowski sold 22,417 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $70.13, for a total value of $1,572,104.21. Following the transaction, the director directly owned 51,326 shares of the company’s stock, valued at approximately $3,599,492.38. The trade was a 30.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski also recently made the following trade(s):

• On Friday, June 12th, Carl Dambkowski sold 12,583 shares of Oruka Therapeutics stock. The stock was sold at an average price of $70.11, for a total value of $882,194.13.
• On Thursday, May 21st, Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $58.97, for a total value of $6,191,850.00.

Oruka Therapeutics Trading Up 2.1%

NASDAQ:ORKA opened at $69.89 on Friday. Oruka Therapeutics, Inc. has a 12 month low of $10.77 and a 12 month high of $91.00. The stock has a 50 day moving average of $63.40 and a two-hundred day moving average of $43.94. The firm has a market cap of $4.22 billion, a P/E ratio of -36.03 and a beta of -0.26.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.04. On average, research analysts forecast that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current year.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc acquired a new stake in Oruka Therapeutics during the second quarter worth $28,000. BNP Paribas Financial Markets increased its stake in Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after acquiring an additional 2,306 shares during the last quarter. Royal Bank of Canada increased its stake in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after acquiring an additional 365 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in Oruka Therapeutics during the fourth quarter worth $37,000. Finally, PNC Financial Services Group Inc. acquired a new position in Oruka Therapeutics during the third quarter worth $39,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Guggenheim set a $200.00 price objective on Oruka Therapeutics and gave the stock a “buy” rating in a research note on Monday, April 27th. Piper Sandler reiterated an “overweight” rating and set a $180.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, April 21st. Finally, BTIG Research reiterated a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a research note on Thursday, May 14th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $131.30.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.